Findings were that in adjuvant breast cancer clinical trials with greater or equal to 4 years follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23-28% of the study participants. The gene discussed is CYP19A1; the disease is breast cancer.